Welcome to our dedicated page for Cabaletta Bio SEC filings (Ticker: CABA), a comprehensive resource for investors and traders seeking official regulatory documents including 10-K annual reports, 10-Q quarterly earnings, 8-K material events, and insider trading forms.
The Cabaletta Bio, Inc. (Nasdaq: CABA) SEC filings page on Stock Titan provides access to the company’s regulatory disclosures as filed with the U.S. Securities and Exchange Commission. As a clinical-stage biotechnology company focused on targeted cell therapies for autoimmune diseases, Cabaletta Bio uses filings such as Forms 8-K, 10-Q and 10-K to report material events, financial results and key developments in its RESET™ clinical program for rese-cel (resecabtagene autoleucel).
Investors reviewing Cabaletta Bio’s filings can find details on quarterly and annual financial performance, including research and development and general and administrative expenses, as well as information on public offerings used to fund clinical and commercial readiness activities. Current reports on Form 8-K often furnish press releases that summarize clinical data from the RESET-Myositis™, RESET-SSc™, RESET-SLE™, RESET-MG™ and RESET-PV™ trials, describe regulatory interactions with the U.S. Food and Drug Administration, and outline registrational cohort designs for rese-cel in specific autoimmune indications.
Filings may also discuss regulatory designations granted to rese-cel, such as Regenerative Medicine Advanced Therapy and Fast Track designations, and PRIME access from the European Medicines Agency, along with updates on chemistry, manufacturing and controls activities and collaborations, including the use of Cellares’ automated Cell Shuttle™ and Cell Q™ platforms for clinical manufacturing and quality control testing. These disclosures help readers understand how Cabaletta Bio is preparing for potential Biologics License Application submissions and future commercialization.
On Stock Titan, Cabaletta Bio’s SEC filings are updated as new documents are posted to EDGAR, and AI-powered summaries can help explain the contents of lengthy reports, such as annual reports on Form 10-K or quarterly reports on Form 10-Q. Users can also monitor Form 8-K filings for material clinical, regulatory or financing events related to rese-cel and the broader CABA™ platform. This page is a resource for analyzing Cabaletta Bio’s regulatory history, financial condition and key milestones in its autoimmune-focused cell therapy programs.
Cabaletta Bio Chief Medical Officer David J. Chang reported buying 8,800 shares of Cabaletta Bio common stock on January 21, 2026. The purchase was made in an open-market transaction coded “P” at a price of $2.26 per share. After this transaction, he directly owns 8,800 common shares of the company.
Cabaletta Bio, Inc. officer Gwendolyn Binder, President, Science & Tech., reported an open-market purchase of company stock. On January 21, 2026, she bought 11,312 shares of Cabaletta Bio common stock at a price of $2.1891 per share.
Following this transaction, Binder directly holds a total of 31,312 shares of Cabaletta Bio common stock, according to the filing.
Cabaletta Bio director reports indirect stock purchase
A reporting person associated with Cabaletta Bio, Inc. bought 22,725 shares of the company’s common stock on January 21, 2026 at a price of $2.2144 per share. Following this transaction, the reporting person is shown as beneficially owning 22,725 common shares, all held indirectly.
The shares are held through an entity named Shawn Tomasello Consulting LLC, rather than in the individual’s direct name. The filing is signed by an attorney-in-fact, indicating the use of an authorized representative to submit the Form 4.
Cabaletta Bio, Inc. insider trade: Chief Commercial Officer Steve Gavel reported purchasing 22,170 shares of Cabaletta Bio common stock on January 21, 2026. The Form 4 shows this as an open-market buy coded "P" at a weighted average price of $2.265 per share.
According to the filing, the shares were acquired in multiple trades at prices ranging from $2.26 to $2.27 per share, and Gavel beneficially owns 22,170 common shares following this transaction, held directly. The insider also notes a commitment to make detailed trade price information available to the company, its security holders, or the SEC staff upon request.
Cabaletta Bio, Inc. director Catherine Bollard reported a purchase of 4,405 shares of the company’s common stock. The transaction took place on 01/21/2026 at a price of $2.2661 per share, according to a Form 4 insider trading report.
Following this open-market purchase, Bollard’s reported beneficial ownership increased to 5,405 shares, held directly. The filing indicates the transaction code "P," which denotes a purchase of non-derivative securities.
Cabaletta Bio, Inc. President & CEO Steven Nichtberger reported buying 45,000 shares of the company’s common stock on January 21, 2026 at a weighted average price of $2.2395 per share. The filing notes these shares were purchased in multiple trades at prices ranging from $2.1985 to $2.26. Following this direct purchase, he beneficially owned 1,031,483 shares held directly.
The Form 4 also shows an additional 363,000 shares reported as indirectly held by the 2017 Nichtberger Family Trust, for which he disclaims beneficial ownership. The price detail and range are available on request from the issuer or the SEC staff, as stated in the footnote.
Cabaletta Bio director Simon Mark reported buying additional company stock. On January 21, 2026, he purchased 11,061 shares of Cabaletta Bio common stock at a weighted average price of $2.2838 per share. The filing notes that these shares were bought in multiple trades at prices ranging from $2.245 to $2.32 and that detailed trade information is available upon request.
After this transaction, Mark beneficially owned 147,205 shares of Cabaletta Bio common stock directly. The filing also reports 7,000 shares held indirectly by his spouse, reflecting additional beneficial ownership connected to him.
Cabaletta Bio, Inc. General Counsel Gerard Michael reported a purchase of 6,600 shares of common stock. The Form 4 shows that on 01/21/2026, he bought 6,600 Cabaletta Bio common shares at a weighted average price of $2.2696 per share, coded as a purchase (P). After this transaction, he beneficially owned 6,600 common shares held directly.
The filing notes that the reported price is a weighted average, with individual purchase prices ranging from $2.269 to $2.2699 per share, and that detailed price breakdowns are available from the company or the reporting person upon request.
Cabaletta Bio filed an 8-K outlining its 2026 strategic priorities for rese-cel, its investigational CD19 CAR T therapy for autoimmune diseases. The company has initiated a dermatomyositis and antisynthetase myositis registrational cohort expected to evaluate 17 patients, targeting a Biologics License Application submission for rese-cel in myositis next year. Cabaletta has aligned with the FDA on new registrational cohort designs in systemic lupus erythematosus and lupus nephritis and received a Regenerative Medicine Advanced Therapy designation for systemic sclerosis, with further regulatory alignment updates planned in
Cabaletta Bio reported a larger quarterly loss as it advanced its cell therapy programs and flagged liquidity risk. For the three months ended September 30, 2025, net loss was $44.9 million, compared with $30.6 million a year ago, driven by higher research and development spending of $39.8 million versus $26.3 million. General and administrative expense was $6.8 million, roughly flat year over year.
Cash, cash equivalents and short‑term investments totaled $159.9 million as of September 30, 2025. The company disclosed that substantial doubt exists about its ability to continue as a going concern, noting current cash, cash equivalents and investments may not fund operations for at least the next twelve months from issuance of the financial statements.
To bolster liquidity, Cabaletta closed a June 2025 financing, raising net proceeds of $93.6 million through common stock, pre‑funded warrants and common stock warrants. As of quarter‑end, 6,000,000 pre‑funded warrants remained outstanding; no common warrants had been exercised. The company also established a $150.0 million at‑the‑market program in August 2025. Voting common shares outstanding were 96,265,204 as of October 31, 2025.